Nancy A Dawson
Overview
Explore the profile of Nancy A Dawson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
2196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Carrasquilla M, Creswell M, Pepin A, Wang E, Forsthoefel M, McGunigal M, et al.
Front Oncol
. 2021 Feb;
10:606260.
PMID: 33537236
Lymph node recurrent prostate cancer is a common clinical scenario that is likely to increase significantly with the widespread adoption of novel positron emission tomography (PET) agents. Despite increasing evidence...
12.
Madan R, Karzai F, Al Harthy M, Petrylak D, Kim J, Arlen P, et al.
BJU Int
. 2020 Sep;
127(4):435-444.
PMID: 32969563
Objective: To evaluate the safety and efficacy of cabozantinib combined with docetaxel. Patients And Methods: This was a phase 1/2 multicentre study in patients with metastatic castration-resistant prostate cancer (mCRPC)....
13.
Apolo A, Nadal R, Tomita Y, Davarpanah N, Cordes L, Steinberg S, et al.
Lancet Oncol
. 2020 Jul;
21(8):1099-1109.
PMID: 32645282
Background: Cabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which also has an effect on the tumour immune microenvironment by decreasing regulatory T cells and myeloid-derived suppressor...
14.
Dawson N, Zibelman M, Lindsay T, Feldman R, Saul M, Gatalica Z, et al.
Mol Cancer Ther
. 2020 Mar;
19(6):1373-1382.
PMID: 32220973
Patients with prostate cancer with tumors harboring defects in DNA-repair genes (DRD) generally do not respond well to AR-directed therapy. Furthermore, canonical pathways evolve during disease progression and may affect...
15.
Wu B, Li S, Song J, Pericone C, Behl A, Dawson N
J Med Econ
. 2019 Oct;
23(1):54-63.
PMID: 31589086
The total cost of healthcare for patients with castration-resistant prostate cancer (CRPC) is an important component for assessing value of treatment options. The need for real-world evidence has increased with...
16.
Hussain M, Tangen C, Thompson Jr I, Swanson G, Wood D, Sakr W, et al.
J Clin Oncol
. 2018 Apr;
36(15):1498-1504.
PMID: 29624463
Purpose Patients with high-risk prostate cancer after radical prostatectomy are at risk for death. Adjuvant androgen-deprivation therapy (ADT) may reduce this risk. We hypothesized that the addition of mitoxantrone and...
17.
Atkins M, Hodi F, Thompson J, Mcdermott D, Hwu W, Lawrence D, et al.
Clin Cancer Res
. 2018 Jan;
24(8):1805-1815.
PMID: 29358500
Pembrolizumab monotherapy, ipilimumab monotherapy, and pegylated interferon alfa-2b (PEG-IFN) monotherapy are active against melanoma and renal cell carcinoma (RCC). We explored the safety and preliminary antitumor activity of pembrolizumab combined...
18.
Pilon D, Behl A, Ellis L, Robitaille M, Lefebvre P, Dawson N
Am Health Drug Benefits
. 2017 Jun;
10(3):143-153.
PMID: 28626511
Background: Central nervous system (CNS) events are frequently reported among patients with advanced prostate cancer as a consequence of the treatments used in this patient population. Objective: To assess the...
19.
Pilon D, Behl A, Ellis L, Emond B, Lefebvre P, Dawson N
J Manag Care Spec Pharm
. 2017 Jan;
23(2):225-235.
PMID: 28125362
Background: Abiraterone acetate (AA) and enzalutamide (ENZ) are oral therapies offering survival benefit to metastatic castration-resistant prostate cancer (mCRPC) patients. Despite the availability of multiple treatment options for mCRPC, there...
20.
Balar A, Galsky M, Rosenberg J, Powles T, Petrylak D, Bellmunt J, et al.
Lancet
. 2016 Dec;
389(10064):67-76.
PMID: 27939400
Background: First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand...